Scientific Publications
-
Combination therapies: a journey into personalized vaccine immunotherapeutics for early-stage cancers
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with Stephen Johnston, CEO, Calviri, about the shift in the I-O space to preventative treatment in combination for early-stage cancers.
-
Design of a randomized, placebo-controlled study evaluating efficacy and safety of a cancer preventative vaccine in dogs
Preventative anti-cancer vaccination strategies have long been hampered by the challenge of targeting the diverse array of potential tumor antigens, with successes to date limited to cancers with viral etiologies…
-
Cancer Vaccine Trials With Canines May Benefit Cancer Prevention in Humans
A first-of-its-kind vaccine for the prevention of cancer in dogs is entering efficacy testing. After 4 years of clinical trials that have all pointed to the vaccine’s capability to stop cancer before it starts, investigators are looking forward to proving it works as intended…
-
Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
Anti-FSP antibodies may serve as biomarkers for predicting ICI outcomes when tested against ligands corresponding to mRNA-error derived FSPs. Model performances suggest this approach…
-
Preventive Cancer Vaccine Based on Neoantigens Gets Put to the Test
Could a vaccine prevent cancer? A canine clinical trial of a neoantigen-based vaccine could open the door for future testing in people…
-
Production of high-complexity frameshift neoantigen peptide microarrays
Parallel measurement of large numbers of antigen–antibody interactions are increasingly enabled by peptide microarray technologies. Our group has developed an in situ synthesized peptide microarray of >400 000 frameshift neoantigens using mask-based photolithographic peptide synthesis, to profile patient specific neoantigen reactive antibodies in a single assay…
-
Antibody characterization using immunosignatures
Therapeutic monoclonal antibodies have the potential to work as biological therapeutics. OKT3, Herceptin, Keytruda and others have positively impacted healthcare. Antibodies evolved naturally to provide high specificity and high affinity once mature. These characteris- tics can make them useful as therapeutics. However, we may be missing characteristics that are not obvious. We present a means of measuring antibodies in an unbiased manner that may highlight therapeutic activity…
-
A Comparison of a DNA-Sourced Neoantigen Vaccine to an RNA-Sourced Frameshift Vaccine in the Mouse Ovarian Cancer Model.
Tumor bearing mice produce antibodies anti-Fs specific that can be detected by peptide microarray…
-
RnA transcription and Splicing errors as a Source of cancer frameshift neoantigens for Vaccines
Calviri is banking on their novel vaccine approach to stop cancer.Their study of RNA processing errors in tumors highlighted that a large number of frameshift neoantigens are produced. This new class of cancer neoantigens are shown in pre-clinical models to serve as protective vaccine components…
-
FAST vaccines based on frameshift neoantigens may have advantages over personal vaccines
The FAST technology may open new opportunities to develop a low cost, feasible and efficacious vaccine against cancer. Personalized and tumor-specific FS vaccines could protect against primary and metastatic lesions in a preclinical mouse model of breast cancer, inducing a potent T cell immune response…
-
Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening
This study introduces the frameshift peptide (FSP) array as a discovery platform for protective cancer neoantigens. Frameshift arrays are shown to be effective for functionally screening possible errors made by tumors at the RNA, not DNA, level for those that generate antibody-reactive neoantigens. Reactive FSPs selected from the array protect vaccinated mice from tumor challenge while non-reactive peptides do not…
-
A simple blood base test for predicting clinical benefit of cancer immunotherapy
The FSPs with positive IgG reactive in response patients may be related to anti-tumor immune response, which needs to be further investigated. We also showed that the FSP array can potentially predict the patients who may have high grade immune related adverse events with the CPI treatment…
-
Common Cancer Neo Antigens from the Frame Shifted Transcripts
The recent breakthrough of cancer immunotherapy with immune checkpoint inhibitors (CPI) not only showed dramatic efficacy in multiple cancer treatments, but also suggested that tumor neo-antigens are the targets of the anti-tumor immune responses that were released by the CPI treatments. The most recently studies of neo-antigen based personalized human melanoma cancer vaccines (PVC) further support this hypothesis by showing efficacy in preventing cancer…
-
Use of Non-Natural Sequence Peptide Arrays to Discover Cancer NeoAntigens For Vaccines and Diagnostics
Neo-antigens from predicted fusion transcripts are targets of cancer humoral immune response. This work indicates that we can efficiently decipher neo-antigens from the immunosignatures of cancer subjects. This may be a new source of antigens for diagnosis and cancer vaccines…
-
The immunosignature of canine lymphoma: characterization and diagnostic application
Cancer diagnosis in both dogs and humans is complicated by the lack of a non-invasive diagnostic test. To meet this clinical need, we apply the recently developed immunosignature assay to spontaneous canine lymphoma as clinical proof-of-concept. Here we evaluate the immunosignature as a diagnostic for spontaneous canine lymphoma at both at initial diagnosis and evaluating the disease free interval following treatment..
-
Immunosignatures can predict vaccine efficacy
The development of new vaccines would be greatly facilitated by having effective methods to predict vaccine performance. Such methods could also be helpful in monitoring individual vaccine responses to existing vaccines. We have developed “immuno- signaturing” as a simple, comprehensive, chip-based method to display the antibody diversity in an individual on peptide arrays. Here we examined whether this technology could be used to develop correlates for predicting vaccine effectiveness…
-
Feasibility of an early Alzheimer's disease immunosignature diagnostic test
A practical diagnostic test is needed for early Alzheimer's disease (AD) detection. Immunosignaturing, a technol- ogy that employs antibody binding to a random-sequence peptide microarray, generates profiles that distinguish transgenic mice engineered with familial AD mutations (APPswe/PSEN1-dE9) from non-transgenic littermates. It can also detect an AD-like signature in humans. Here, we assess the changes in the immunosignature at differ- ent time points of the disease in mice and humans…
-
Application of Immunosignatures to the Assessment of Alzheimer’s Disease
Accurate assessment of Alzheimer’s disease (AD), both presymptomatically and at different disease stages, will become increasingly important with the expanding elderly population. There are a number of indications that the immune system is engaged in AD. Here we explore the ability of an antibody-profiling technology to characterize AD and screen for peptides that may be used for a simple diagnostic test…